General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients.
Last updated June 20, 2024
Status:
Concluded with an LOI
Manufacturer:
Sandoz Canada Inc.
Indication:
Multiple Indications
Last updated June 19, 2024
Status:
Concluded without agreement
Manufacturer:
Arcutis Biotherapeutics, Inc.
Indication:
Plaque psoriasis
Last updated June 14, 2024
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Primary hyperlipidemia and mixed dyslipidemia
Last updated June 3, 2024
Wyost (denosumab 120 mg/1.7 mL)
Status:
Concluded with an LOI
Manufacturer:
Sandoz Canada Inc.
Indication:
Multiple Indications
Last updated May 24, 2024
Status:
Concluded with an LOI
Manufacturer:
Sandoz Canada Inc.
Indication:
Multiple Indications
Last updated May 24, 2024
Status:
Concluded without agreement
Manufacturer:
ViiV Healthcare
Indication:
HIV-1 infection, in combination with other antiretroviral agents, in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations
Last updated May 22, 2024
Maviret (glecaprevir/pibrentasvir granules)
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Chronic Hepatitis C (Pediatric)
Last updated May 23, 2024
Status:
Concluded without agreement
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Metastatic Pancreatic Cancer
Last updated May 16, 2024
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
COVID-19
Last updated May 10, 2024